Urolithin A
Urolithin A scored 6.5 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Exogenous Metabolite.
Urolithin A is a pomegranate-and-walnut metabolite that supports mitophagy. Andreux 2019 showed safety and mitochondrial biomarker shifts, while the 2024 human systematic review found promising but insufficient functional evidence.
What is Urolithin A?
Urolithin A is a gut-microbial metabolite made when certain bacteria convert ellagitannins from pomegranate, walnuts, raspberries, and related foods. The supplement version bypasses that gut-conversion step and directly supplies the metabolite, which matters because many adults are low or non-producers. In plain English: urolithin A is a mitochondrial cleanup signal, not an acute energy pill.
The core mechanism is selective mitophagy, the cell's process for tagging and clearing damaged mitochondria. Urolithin A is linked to the PINK1 / Parkin pathway, where damaged mitochondria are flagged for recycling. Ryu 2016 established the foundational preclinical signal in worms and rodents, and Andreux 2019 moved the molecule into humans by showing safety, bioavailability, acylcarnitine changes, and mitochondrial gene-expression shifts.
The current v1.0 score stays at 6.8 because the human signal is real but still narrow. The best evidence supports mitochondrial biomarkers and modest muscle-function endpoints, especially in older or lower-baseline adults. Liu 2022 found muscle-endurance and biomarker improvements in older adults, but not clear between-group significance for 6-minute walk distance or maximal ATP production. Hodzic Kuerec 2024 is the right tempering source: the review found some mitochondrial, autophagy, fatty-acid oxidation, and inflammation signals, but no clear effect on cardiovascular outcomes, anthropometrics, gut microbiota composition, or broad physical function.
That makes urolithin A a good candidate for a measured 12-16 week personal trial, especially if you are older, sedentary, post-illness, or suspect poor mitochondrial resilience. It is less compelling as a daily forever supplement for young, fit, metabolically healthy people who already train, sleep, eat protein, and cover the cheaper mitochondrial basics.
Terminology
For the microbiome conversion bottleneck, see the Gordonibacter discovery paper from Selma 2014.
- Ellagitannins: Polyphenols found in pomegranate, walnuts, raspberries, blackberries, and oak-aged foods. Gut bacteria break them down into ellagic acid and urolithins.
- Urolithin A: The urolithin congener with the strongest mitophagy-support signal in the human supplement literature.
- Mitophagy: Selective recycling of damaged mitochondria. It is narrower than general autophagy.
- PINK1 / Parkin pathway: A mitochondrial quality-control pathway that tags damaged mitochondria for cleanup.
- Mitopure: The micronized urolithin A preparation from Amazentis / Timeline used in the main published human RCTs.
- Amazentis: Swiss biotechnology company behind Mitopure and several urolithin A human trials.
- Non-producer: A person whose gut microbiome makes little or no urolithin A from ellagitannin foods.
- Colonic bioconversion: Gut-bacteria conversion of ellagitannins into urolithins in the colon.
- Acylcarnitines: Fatty-acid transport intermediates that can reflect mitochondrial beta-oxidation stress when elevated.
- Gordonibacter: A gut-bacterial genus involved in urolithin production from ellagic acid.
- ATLAS trial: A 4-month urolithin A trial in middle-aged adults measuring muscle strength, exercise performance, and mitochondrial biomarkers.
- GRAS: Generally Recognized As Safe. For urolithin A, this refers to specified food-ingredient use, not drug approval.
- NOAEL: No-Observed-Adverse-Effect Level, a toxicology threshold where no adverse effect is detected at the tested dose.
How do you take Urolithin A?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule (Mitopure) | Softgel capsule containing micronized urolithin A | 500-1000 mg/day | 500-1000 mg/day |
| Oral powder | Pouched urolithin A powder mixed into yogurt, smoothie, or water | 500 mg/day | 500 mg/day |
| Food (ellagitannin precursor) | Pomegranate juice or arils, walnuts, raspberries, blackberries, and related ellagitannin-rich foods | No standardized clinical urolithin A dose from food | 1-2 cups pomegranate juice plus 30 g walnuts daily |
Protocols
Standard Mitopure trial Clinical
- Dose
- 500 mg/day
- Frequency
- Daily with breakfast or another meal
- Duration
- 12-16 weeks minimum
Best default for a personal trial. Biomarker shifts may appear by 4 weeks; functional strength and endurance signals require closer to 4 months.
Higher-dose non-responder trial Mixed
- Dose
- 1000 mg/day
- Frequency
- Daily
- Duration
- 8-12 weeks after an initial 500 mg/day trial
Reasonable only if cost is acceptable and 500 mg/day produces no subjective or biomarker shift. Evidence does not make this the default starting dose.
Food-first producer screen Anecdotal
- Dose
- 1-2 cups pomegranate juice plus 30 g walnuts daily
- Frequency
- Daily
- Duration
- 4-8 weeks
Cheapest entry point for likely producers. If nothing changes and producer testing is unavailable, direct urolithin A is the cleaner experiment.
Training-block support Mixed
- Dose
- 500 mg/day
- Frequency
- Daily during heavy training or recovery blocks
- Duration
- 12-16 weeks aligned with a training mesocycle
Built from muscle endurance trials, not proven cycling data. Best suited to older or lower-baseline users, not already-optimized athletes.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Urolithin A?
Upside contribution: 1.85
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.7 | 0.675 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 2.8 | 0.700 | |
| Speed | 10% | 2.3 | 0.230 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality | 15% | 3.6 | 0.540 | |
| Total | 2.845 |
Upside Rationale
Urolithin A has real upside when the use case matches its best evidence, especially around mitochondrial quality control, muscle endurance, and inflammatory aging. The honest version of the urolithin A story is not the headline mechanism. It is the chance to connect urolithin A to a measurable outcome and watch whether the expected change actually appears. The upside is strongest for users with the relevant baseline problem, weaker for already optimized users chasing a vague edge, and most credible when paired with tracking. For this report, urolithin A earns credit for plausible mechanisms, genuine human anchors where they exist, and a real bioindividual advantage for non producers. The right read is targeted, time bound use, not automatic daily inclusion for everyone.
Efficacy. Urolithin A produces real but modest functional benefit in humans, and the strongest part of the data is biomarker movement rather than performance you can feel. Liu 2022 found muscle endurance and mitochondrial biomarker improvements, while the main walking distance and maximal ATP endpoints did not clearly beat placebo. The surrogate mitophagy and acylcarnitine shifts are consistent but are not credited here as outcomes, because biomarker change is not the same as a benefit a person experiences. Watts 2025 is the key caution: current functional evidence does not yet support broad muscle function claims. Urolithin A is best understood as a small, real, single domain effect.
Breadth of benefits. Urolithin A touches three human relevant systems: mitochondrial quality control, muscle endurance or strength, and inflammatory or immune aging. Denk 2025 adds a new immune aging signal with CD8 and fatty acid oxidation changes after four weeks. But the breadth of urolithin A has a single common root, which is mitophagy, so this is not a true multi system intervention like exercise or sleep. No compelling completed human data support cardiovascular, cognitive, sleep, hormonal, sexual health, or body composition claims for urolithin A yet, despite active commercial interest in extending it into those categories.
Evidence quality. Urolithin A has genuine human RCTs, which is rare for a longevity supplement, but the evidence base is capped by funding capture rather than by study format. Hodzic Kuerec 2024 reviewed five human studies in 250 healthy individuals and concluded more research is needed across longer periods and more systems. Andreux 2019 and Liu 2022 are useful, but the core trials share single sponsor funding and investigator overlap, so independent replication is thin. That single source concentration, not a lack of randomized trials, is what keeps urolithin A out of high confidence territory for now.
Speed of onset. Urolithin A is slow, and anyone expecting a same day lift will be disappointed. Andreux 2019 found molecular and acylcarnitine shifts at four weeks, which is the earliest credible benchmark for urolithin A. The endurance and strength related outcomes in the main human trials require closer to four months. That makes urolithin A faster than some long horizon longevity inputs but far slower than anything acute. In practice, the sensible personal trial window for urolithin A is twelve to sixteen weeks, with objective tracking where possible, so the slow timeline is built into the plan rather than mistaken for failure.
Durability. Urolithin A benefits depend on continued daily dosing, so the durability is moderate rather than near zero or permanent. No published human washout trial shows that urolithin A produces a lasting reset after stopping, and the pharmacokinetics suggest circulating exposure falls within days while the mitophagy signal likely fades over subsequent weeks. Heilman 2017 supports safety margins, not persistence. The fairest framing is that urolithin A is a maintenance input: any lasting benefit would come from improved training capacity and recovery accumulated while using it, not from a proven durable molecular change that survives discontinuation.
Bioindividuality. Urolithin A has a real, mechanistic bioindividual advantage that most supplements lack, because direct dosing bypasses the gut microbiome conversion step entirely. Tomas-Barberan 2017 shows that adults differ substantially in their ability to make urolithin A from dietary ellagitannins, so many people are low or non producers no matter how many pomegranates or walnuts they eat. For those non producers, supplemental urolithin A is the only reliable route to meaningful exposure, which is a concrete and identifiable advantage. Producers, younger fit adults, and metabolically healthy users are the least likely to notice anything from added urolithin A.
What are the risks & downsides of Urolithin A?
Downside contribution: 0.66 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.4 | 0.420 | |
| Side effects | 15% | 1.4 | 0.210 | |
| Cost | 5% | 4.3 | 0.215 | |
| Effort | 5% | 1.3 | 0.065 | |
| Opportunity | 5% | 2.0 | 0.100 | |
| Dependency | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.535 | |||
| Harm subtotal × 1.4 | 1.617 | |||
| Opportunity subtotal × 1.0 | 0.380 | |||
| Combined downside | 1.997 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.657 |
Downside Rationale
Urolithin A's downside is the gap between a plausible, modest benefit and the cost and uncertainty required to test it. The caution side of urolithin A is not really safety, because it tolerates well in healthy adults. It is the combination of high branded price, evidence that leans on surrogate markers, and a benefit that only clearly shows up in the best matched population. Urolithin A deserves extra care when users are pregnant, nursing, medically complex, or trying to substitute it for proven care. The practical orientation is simple: start with the lowest risk version of urolithin A, keep the trial time bound, track an objective marker, and stop when cost, unclear benefit, or a stronger alternative makes the case.
Safety risk. Urolithin A has a low safety risk profile in healthy adults, with the main caveat that long term and special population data remain limited. Heilman 2017 found no genotoxicity and a high rodent no observed adverse effect level for urolithin A. Andreux 2019 and later human trials reported favorable short term tolerability. Food ingredient safety status supports use as a supplement, not therapeutic approval, so urolithin A should not carry disease treatment claims and should be avoided in pregnancy, nursing, pediatric use, and unsupervised oncology contexts. There is no approval for urolithin A to treat aging, muscle, mitochondrial, cognitive, or cancer conditions.
Side effect profile. Urolithin A side effects are usually mild when they appear at all. Published trials report low rates of complaints such as headache, muscle soreness, or mild GI discomfort, generally without clear separation from placebo. Denk 2025 adds short term high dose immune aging data for urolithin A without changing the overall safety picture. The side effect score for urolithin A stays near the floor because no signal of endocrine disruption, sleep disturbance, withdrawal, or clinically meaningful lab deterioration has emerged in the verified corpus. The real open question is not acute tolerability but long term daily use beyond the short RCT windows.
Financial cost. Cost is the strongest single downside of urolithin A, because only branded Mitopure has actually been validated in the human RCTs. That branded product commonly runs around fifty to one hundred dollars per month at the studied dose, which is expensive next to creatine, magnesium, protein, or basic mitochondrial cofactors. Generic urolithin A is cheaper, but no trial establishes that generic material matches the studied product, and the supplement category has genuine purity and label claim problems. So the validated version of urolithin A is costly and the affordable version is unproven, which is a real bind for any budget conscious user.
Time and effort burden. Urolithin A is almost frictionless to use. One daily capsule or powder serving takes seconds, with no cycling requirement, no device setup, no fasting window, and no complicated timing beyond taking urolithin A consistently. The only optional overhead is measurement, such as inflammatory markers, strength testing, or repeat endurance testing if you want to know whether urolithin A is doing anything for you. Compared with cold exposure, sauna, photobiomodulation, or strict diet protocols, the daily effort burden of urolithin A is near the floor. The genuinely hard part is staying patient across the twelve to sixteen week window.
Opportunity cost. Urolithin A stacks cleanly with exercise, protein, creatine, mitochondrial nutrients, spermidine, and sleep work, so the displacement is financial rather than practical. At fifty to one hundred dollars per month, branded urolithin A competes directly with higher confidence basics and with other longevity supplements. Food first producers can get some exposure from pomegranate and walnuts, but non producers need direct urolithin A for reliable levels. The opportunity cost reflects that tradeoff: paying for a biomarker forward intervention with single sponsor evidence means not paying for something with stronger independent clinical validation behind it.
Dependency and withdrawal. Urolithin A has no documented dependency, tolerance, withdrawal syndrome, receptor downregulation, or tapering requirement, though the continuation pull is slightly above zero because benefits fade once dosing stops. The mechanism behind urolithin A is a mitochondrial quality control support signal, not a hormone, stimulant, sedative, or neurotransmitter agonist. Stopping urolithin A simply removes the supplemental exposure and lets the biomarker signal drift back down over weeks, which is discontinuation of a maintenance input rather than true withdrawal. Users can start, pause, restart, or reserve urolithin A for specific blocks without a physiological dependency concern based on current human evidence.
Reversibility. Urolithin A is fully reversible as a practical intervention. There is no procedure, implant, tissue ablation, gene edit, or permanent endocrine change involved in taking urolithin A. The compound and its conjugates clear after stopping, and any biomarker shift should drift back toward baseline unless maintained by other inputs. The only uncertainty is exactly how quickly muscle and mitochondrial markers revert, because human washout data for urolithin A are missing. That uncertainty limits durability confidence rather than creating a safety penalty. In daily life terms, if urolithin A is not helping, you simply stop taking it.
Is Urolithin A worth it?
Urolithin A is a 6.5 / 10 fit for people considering mitochondrial, muscle growth, endurance cardio, anti inflammatory, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Hodzic 2024 and Watts 2025 give the report its main anchors, while the score stays worth trying because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Urolithin A makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Urolithin A as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Older adults, sedentary adults, post-illness rebuild phases, and people who suspect poor mitochondrial resilience but want a low-effort intervention. Urolithin A is also more compelling if you are a likely non-producer from ellagitannin foods, because direct supplementation bypasses the gut-bacteria bottleneck described by Selma 2014. Use Mitopure if you want the closest match to the human trial literature. Run it for 12-16 weeks, track something objective, and treat biomarker improvements as more likely than a dramatic felt energy change.
❌ Avoid if: You are price-sensitive, already highly fit, pregnant, nursing, buying unverified generics, or expecting a fast subjective nootropic or energy effect. Avoid using urolithin A as a cancer, cognition, cardiovascular, hormone, or disease-treatment intervention. Francisco 2026 is preclinical colorectal-cancer synthesis, not human treatment evidence. Athletes should also remember that urolithin A was not found as a named WADA-banned substance in the audit, but supplement contamination and label risk still apply.
What is Urolithin A best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 7.0/10
Score: 7.0/10Urolithin A earns 7.0/10 for mitochondrial; this is a targeted fit score. Core use case. Andreux 2019 found safety, bioavailability, acylcarnitine shifts, and mitochondrial gene-expression changes after regular urolithin A intake. That makes Urolithin A more defensible when mitochondrial is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the mitochondrial marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Muscle Growth / Hypertrophy: 5.0/10
Score: 5.0/10For muscle growth, Urolithin A lands at 5.0/10 because context matters. Human data support a modest muscle-performance signal more than hypertrophy. ATLAS and older-adult trials suggest strength/endurance effects, but not clear muscle-mass gain. That makes Urolithin A more defensible when muscle growth is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the muscle growth marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Anti-Inflammatory: 5.5/10
Score: 5.5/10For readers prioritizing anti inflammatory, Urolithin A scores 5.5/10 today. Denk 2025 and the 2024 systematic review support anti-inflammatory and immune-metabolic signals, though disease-level inflammation outcomes are unproven. That makes Urolithin A more defensible when anti inflammatory is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the anti inflammatory marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Healthspan: 5.0/10
Score: 5.0/10The healthspan score is 5.0/10, and Urolithin A needs careful framing. Mitochondrial quality control is a credible healthspan target, but human functional endpoints remain early. The healthspan score reflects mechanism plus small trials, not proven aging modification. That makes Urolithin A more defensible when healthspan is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the healthspan marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Geriatric / Aging Population: 5.5/10
Score: 5.5/10The 5.5/10 geriatric score reflects evidence plus practical constraints. Older adults are the best-studied human group. Liu 2022 studied adults aged 65-90 and found muscle-endurance plus biomarker signals. That makes Urolithin A more defensible when geriatric is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the geriatric marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Longevity / Lifespan: 5.0/10
Score: 5.0/10Urolithin A gets 5.0/10 for longevity; the evidence supports a narrow read. Ryu 2016 found lifespan extension in C. elegans and improved muscle function in rodents. Human lifespan evidence does not exist. That makes Urolithin A more defensible when longevity is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the longevity marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Autophagy: 5.0/10
Score: 5.0/10Urolithin A fits autophagy at 5.0/10 when the baseline problem is real. Urolithin A is best described as a selective mitophagy support compound, not a broad autophagy inducer. Andreux 2019 supports the human biomarker signature. That makes Urolithin A more defensible when autophagy is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the autophagy marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
| Use Case | Score | Summary |
|---|---|---|
| ○ Endurance / Cardio Primary | 4.5 | Liu 2022 found muscle-endurance and biomarker benefits in older adults, while walking-distance and ATP-production endpoints were not clearly significant vs placebo. |
| ○ Immune Function | 4.5 | Denk 2025 reported a 4-week immune-aging signal with naive-like CD8+ cell expansion and improved immune-cell fatty-acid oxidation. Useful signal, still early. |
| ○ Strength / Power | 4.5 | The middle-aged ATLAS trial reported strength signal at 500 mg/day, but the finding is single-source and industry-linked. Independent replication would materially raise confidence. |
| ○ Recovery / Repair | 4.0 | Mitochondrial renewal could support recovery capacity, but direct human recovery endpoints are limited. Treat this as a secondary inference from muscle and biomarker data. |
| ○ Cellular Senescence | 4.0 | Damaged mitochondria are associated with cellular aging, so the mitophagy mechanism is relevant. Direct human senescence-marker evidence is still insufficient. |
| ○ Energy / Fatigue | 4.0 | Mitochondrial biomarker changes can translate into energy for some low-baseline users, but subjective energy reports are mixed and not a proven acute effect. |
| ○ Metabolic Health | 3.5 | Downstream mitochondrial signal only. Hodzic Kuerec 2024 found no clear anthropometric or broad metabolic outcome effect in humans. |
| ○ Cardiovascular | 3.0 | Indirect mitochondrial and anti-inflammatory pathway only. Hodzic Kuerec 2024 found no clear cardiovascular outcome effect across the small human study base. |
Frequently Asked Questions
What is urolithin A and how does it actually work?
Urolithin A supports selective mitochondrial cleanup, not a stimulant-like energy pathway. Gut bacteria make it from ellagitannins in foods like pomegranate and walnuts, then the molecule supports mitophagy through PINK1 / Parkin quality-control signaling. Andreux 2019 found that 4 weeks of oral urolithin A changed plasma acylcarnitines and skeletal-muscle mitochondrial gene expression in older adults.
Can I just eat pomegranate and walnuts instead of supplementing?
Sometimes, but only if your gut bacteria can convert ellagitannins into urolithin A. Selma 2014 identified Gordonibacter as a urolithin-producing gut bacterium, and metabotype research shows large person-to-person differences. If you are a low or non-producer, food-first intake may still be healthy but will not reliably raise urolithin A to trial-like exposure.
Is Mitopure actually better than generic urolithin A capsules?
Mitopure is the evidence-matched choice because it is the preparation used in the main published human trials. The issue is not branding alone; the human evidence is tied to a specific micronized urolithin A preparation with documented bioavailability. Generic capsules may be cheaper, but bioequivalence and purity are not established in the RCT literature. If you are testing whether the human trial signal applies to you, Mitopure is the cleaner experiment.
What is the right dose of urolithin A, 500 or 1000 mg?
Start with 500 mg/day unless you have a reason to pay for more. Human trials have used both 500 and 1000 mg/day, but the higher dose has not clearly beaten 500 mg/day for most practical endpoints. Take it daily with breakfast or another meal. A 1000 mg/day trial is reasonable after 8-12 weeks at 500 mg if you have no subjective or biomarker response and cost is not the limiting factor.
Does urolithin A actually improve muscle strength and endurance?
Urolithin A has a small muscle-performance signal, but the evidence is not settled. Liu 2022 found muscle-endurance and biomarker benefits in older adults, while 6-minute walk distance and maximal ATP production were not clearly significant vs placebo. Watts 2025, Hodzic Kuerec 2024, and the Andreux human biomarker trial all support a cautious read: functional evidence is not strong enough for routine muscle-function claims.
Is urolithin A safe? Any side effects?
Urolithin A looks low-risk in healthy adults, but long-term and special-population data are limited. Heilman 2017 found a high rodent no-observed-adverse-effect level, and Andreux 2019 reported favorable short-term human safety. Mild headache, muscle soreness, or GI complaints can happen, but published trials have not shown a major side-effect burden. Avoid pregnancy, nursing, pediatric use, and disease-treatment claims without clinician guidance.
How long until I notice anything from urolithin A?
Expect biomarkers before felt benefits. Andreux 2019 found mitochondrial biomarker shifts after 4 weeks, while muscle-performance signals in the main trials used roughly 4 months of daily dosing. Subjective energy is inconsistent, especially in already-fit users. Give urolithin A 12-16 weeks before judging it, and use objective strength, endurance, or lab markers if possible.
What stacks well with urolithin A, NMN or spermidine?
The cleaner stack logic is urolithin A for mitophagy, an NAD+ precursor such as NMN for mitochondrial fuel signaling, and spermidine for broader autophagy. That said, no RCT has proven this combination beats urolithin A alone. I would not stack three expensive longevity supplements until each one has individually earned its place for your goal.
What could change Urolithin A's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Independent academic lab replicates muscle and endurance outcomes | Evidence 2.5 to 3.5; Efficacy 2.5 to 3.0 | 6.8 / 10 👍 Worth trying |
| 650-person brain-health trial shows clinically meaningful cognitive benefit | Breadth 2.8 to 3.5; Efficacy 2.5 to 3.0 | 6.7 / 10 👍 Worth trying |
| Price drops to $20/month with independently verified generic quality | Cost 3.5 to 2.0 | 6.6 / 10 👍 Worth trying |
| Long-term study shows no functional benefit despite biomarker shifts | Efficacy 2.5 to 1.8 | 6.2 / 10 👍 Worth trying |
| Independent review finds a meaningful long-term safety or interaction signal | Safety 1.2 to 2.2; Side effects 1.2 to 2.0 | 5.9 / 10 👍 Worth trying |
| Cochrane or specialty-society review recommends against routine use | Evidence 2.5 to 2.0; Opportunity 2.0 to 2.5 | 6.2 / 10 👍 Worth trying |
Key Evidence Sources
- Hodzic Kuerec et al. 2024 - Targeting aging with urolithin A in humans: systematic review, Ageing Research Reviews. Five human studies, 250 healthy individuals; anti-inflammatory and mitochondrial/autophagy marker signals, but insufficient evidence for broad physical-function or cardiovascular claims.
- Watts et al. 2025 - The effects of urolithin A supplementation on muscle strength, muscle mass and physical performance in humans: systematic review, medRxiv. Preprint synthesis of three randomized trials; pooled 6-minute walk estimate crossed null and conclusion said evidence remains insufficient for current muscle-function use.
- Francisco et al. 2026 - Unveiling the Anticancer Potential of Urolithin A in Colorectal Cancer: systematic review, Oncology Research. In vitro colorectal-cancer review; preclinical anticancer signals but no basis for human cancer-treatment claims.
- Andreux et al. 2019 - The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans, Nature Metabolism. Corrected PMID for the first-in-human urolithin A study; supports safety, bioavailability, acylcarnitine shifts, and mitochondrial gene-expression effects.
- Liu et al. 2022 - Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults, JAMA Network Open. Older-adult RCT; muscle-endurance and biomarker signals, but 6-minute walk and maximal ATP production were not clearly significant vs placebo.
- Singh et al. 2022 - Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in middle-aged adults, Cell Reports Medicine. Middle-aged adult RCT; supports strength and performance signal, with industry funding and replication limitations.
- Denk et al. 2025 - Effect of the mitophagy inducer urolithin A on age-related immune decline, Nature Aging. 50-person RCT; 1000 mg/day for 4 weeks shifted CD8+ immune-aging and fatty-acid oxidation endpoints.
- Heilman et al. 2017 - Safety assessment of Urolithin A, Food and Chemical Toxicology. Rodent toxicology and genotoxicity assessment; high no-observed-adverse-effect level and no target-organ toxicity at tested doses.
- Ryu et al. 2016 - Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents, Nature Medicine. Foundational preclinical mitophagy paper; lifespan and muscle-function signals in worms and rodents.
- Tomas-Barberan et al. 2017 - Urolithins and metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status, Molecular Nutrition and Food Research. Review of urolithin metabotypes and interindividual variability in ellagitannin conversion.
- Selma et al. 2014 - Gordonibacter urolithinfaciens sp. nov., a urolithin-producing bacterium isolated from the human gut, International Journal of Systematic and Evolutionary Microbiology. Identified a human-gut bacterium capable of producing urolithins from ellagic acid.
- Selma et al. 2018 - Urolithin metabotypes after pomegranate or walnut ellagitannins and cardiometabolic biomarkers, Clinical Nutrition. Human metabotype study linking urolithin-production patterns with cardiometabolic-risk biomarkers.
- D'Amico et al. 2022 - Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis, Aging Cell. Preclinical OA model plus human chondrocyte work; useful for mechanism, not direct human joint-efficacy claims.
- Madsen et al. 2024 - Urolithin A and nicotinamide riboside differentially regulate innate immune defenses and metabolism in human microglial cells, Frontiers in Aging Neuroscience. Human microglial-cell study; supports neuroimmune mechanism exploration without proving clinical cognitive benefit.
- Hou et al. 2024 - Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions, Alzheimer's and Dementia. Preclinical Alzheimer's-model study; relevant to brain-health hypothesis but not a human cognition claim.
- FDA GRAS Notice inventory - Urolithin A GRN 791. Lists FDA GRAS Notice Number 791 with no-questions status for specified food-ingredient uses; not drug approval.
- ClinicalTrials.gov NCT07060898 - Radicle Clarity brain longevity supplement trial with urolithin A. Registered 650-participant cognitive-function trial; no posted peer-reviewed results at the time of this v1.0 drain.
What does the evidence say about Urolithin A?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Andreux 2019, Liu 2022, Singh 2022, Hodzic Kuerec 2024, Denk 2025, Watts 2025, Francisco 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Selma 2014, Tomas-Barberan 2017
Traditional Medicine Systems
Confidence: Limited
Holistic Evidence for Urolithin A
Modern, historical, and traditional lenses converge on ellagitannin-rich foods as meaningful human exposures, but they diverge on what is being tested. Traditional and historical use point to pomegranate and walnuts as foods; modern trials test purified urolithin A that bypasses gut conversion. Honest synthesis: urolithin A is not just pomegranate in capsule form. It is a targeted postbiotic strategy for people who may not convert those foods efficiently, with stronger biomarker evidence than outcome evidence.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Lactate Baseline (pre-protocol) During | Expected Down
- hs-CRP During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- Creatine Kinase During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Primary
- Drive During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Muscle Endurance Scale 1-5 | During | Expected Up
- Exercise Soreness Scale 1-5 | During | Expected Down
- GI Comfort Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Persistent GI distress
- New muscle weakness
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.845 − 0.657 = 1.188
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.188 / 4.00) × 5 = 6.5 / 10
